How to Trip Rapid Review
Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)
Step 2: press
Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.
- 734 results
- Evidence type
- Clinical Area
Use check boxes to select individual results below
SmartSearch available
Trip's SmartSearch engine has discovered connected searches & results. Click to show241. Satiety Innovation- Study 793. University of Aberdeen
, history of gastric bezoar. Suspected strictures, fistulas, or physiological GI obstruction. Psychiatric disorder: severe depression, bulimia, anorexia, schizophrenia, bipolar disorder. Gastrointestinal procedure or surgery in the past three months. Disorders of swallowing, severe dysphagia to food or pills. Pregnancy Medication exclusion criteria Appetite modulator drugs: orlistat, sibutramine, rimonabant. Mood disorder medications: antidepressants, lithium. Others: oral antidiabetics, insulin
2012 Clinical Trials
242. Assessment of Energy Balance
an 8 week weight loss diet, consisting of supplement or powdered shakes, portion-controlled entrees, or home-cooked meals. Exclusion Criteria: A diagnosis of diabetes, cardiovascular disease, or cancer. Females who are pregnant or planning to become pregnant during the trail. Medications that influence appetite or body weight (weight loss medications such as sibutramine, antipsychotic medications such as olanzapine, or herbal weight loss products) taken during the previous three months. Contacts
2012 Clinical Trials
243. Placebo Controlled Trial of Dextromethorphan in Rett Syndrome
medical illnesses such as vasculopathies, malignancies, diabetes, thyroid dysfunction, etc; those on medications that could interact with DM, e.g. MAO inhibitors, SSRI, sibutramine etc. to avoid a serotonin syndrome; quinidine and drugs metabolized by the CYP450 isoform CYP2D6 (e.g. amiodarone, haloperidol, propafenone, thioridazine); those proven to be intermediate or slow metabolizers of DM; those with reported adverse reactions to DM; those whose pregnancy test is positive; those showing poor
2012 Clinical Trials
244. Palatability (Energy I Pilot)
use prescriptions or over-the-counter medications or herbal products that affect metabolism or body weight (e.g. weight loss medications such as sibutramine, or orlistat). You have symptoms of depression or excessive dietary restraint. You have an allergy to one or more of the test foods. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided
2012 Clinical Trials
245. Slowing HEART diSease With Lifestyle and Omega-3 Fatty Acids
for weight loss [eg Xenical (orlistat), Meridia (sibutramine), Acutrim (phenylpropanolamine) or similar over-the-counter medications] within three months of screening surgery within 30 days of screening history of acquired immune deficiency syndrome or human immunodeficiency virus (HIV) poor mental function or history of dementia/Alzheimer's Disease or on medications used for treatment of dementia [e.g. Tacrine (Cognex), Rivastigmine (Exelon), Galantamine (Razadyne, Reminyl), Donepezil (Aricept
2012 Clinical Trials
246. Evaluating the Health Benefits of Physical Activity Recommendations in the Dietary Guidelines
10 lbs in the preceding 6 months Medications: chronic corticosteroid use or need for oral corticosteroids more than twice in the last 12 months, antipsychotic medications, beta adrenergic blockers, medications for weight loss (including sibutramine, orlistat, phentermine, phendimetrazine, topiramate, zonisamide), immunosuppressants, amphetamines and other stimulants, and other medications known to influence body weight Travel plans that do not permit full participation Contacts and Locations Go
2012 Clinical Trials
247. Positive Energy I Through Overfeeding
, appetite, or metabolism, such as diabetes and cardiovascular disease. You have irregular menstrual cycles, had a partial hysterectomy (still maintain ovaries), or use an IUD not made of copper. You use prescriptions or over-the-counter medications or herbal products that affect metabolism or body weight (e.g. weight loss medications such as sibutramine, or orlistat). You use a birth control pill that isn't monophasic or you receive Depro-Provera injections. You have barriers to completing the study
2012 Clinical Trials
248. Effect on Liver Histology of Vitamin D in Patients With Non-alcoholic Steatohepatitis
, sibutramine. Oral hypoglycaemic agents and insulin will be allowed, provided they had been initiated at least 6 months before enrollment and are maintained at stable doses. Ongoing or recent therapy (within 6 months of baseline liver biopsy and screening visit) with vitamin D or with medications known to affect vitamin D3 metabolism, including vitamin/mineral supplements. Any additional condition that might interfere with optimal participation in the study, according to Investigators opinion. Be pregnant
2012 Clinical Trials
249. Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma
<1.5X109/L, platelets < 50X109/L. Serious comorbidity that may impair the ability to complete the study (such as severe heart disease, severe pulmonary hypertension) and other comorbidities. Prednisone at doses of >10mg/od. Other potential disease modifying drugs such as cyclophosphamide, mycophenylate and methotrexate. Serious liver disease. Creatinine >200. Excluded: Ketoconazole and fluconazole, cyclosporine, rifampin, phenytoin nefazodone, pimozide, propafenone, quinidine, sibutramine
2012 Clinical Trials
250. Full4Health: Understanding Food-gut-brain Axis Across the Lifecourse
disease Multiple Sclerosis Parkinsons disease Medication known to influence appetite (orlistat, oral antidiabetics, insulin, digoxin, anti-arrhythmics, sibutramine, antidepressants) Self report fever/systemic infection Inability to participate in fMRI scanning sessions including contraindications to MRI Participation in medical or surgical weight loss programme within 1 month of selection History of cerebrovascular disease Current major depressive disorder, bipolar disorder or past history of suicide
2012 Clinical Trials
251. The PRIMAVERA Study: Reduxine Safety Monitoring in Patients With Alimentary Obesity
artery disease (e.g. angina, myocardial infraction); congestive heart failure; tachycardia; peripheral arterial occlusive disease; arrythmia; Uncontrolled arterial hypertension >145/90 mm Hg; Hypersensitivity to sibutramine or any components of Reduxine®; Current use of monoamineoxidase inhibitors (IMAO) or their use within the last 2 weeks; Current use of other central acting weight reducing drugs or their use within the last 2 weeks; Use on other drugs affecting the central nervous system (e.g
2012 Clinical Trials
252. Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis
, moxifloxacin, nilotinib, norepinephrine, ondansetron, oxytocin, paliperidone, perflutren lipid microspheres, phentermine, phenylephrine, phenylpropanolamine, protriptyline, pseudoephedrine, ranolazine, ritodrine, toxithromycin, sibutramine, solifenacin, sunitinib, tacrolimus, telithromycin, terbutaline, terfenadine, tolterodine, trimethoprim-sulfa, vandetanib, vardenafil, voriconazole. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your
2012 Clinical Trials
253. Toxicity of Weight Loss Agents (Full text)
, phenylpropanolamine, ma huang/ ephedra, caffeine, clenbuterol, fenfluramine, sibutramine, thyroid hormone, orlistat and cannabinoid antagonists.With the internet making even banned products readily accessible, healthcare providers need to be aware of the potential toxicities of a wide range of weight loss agents. Our review covered topics we thought to be most historically significant as well as pertinent to the practice of medical toxicology today.
2012 Journal of Medical Toxicology PubMed abstract
254. Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes. (Full text)
Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes. The optimal HbA(1c) concentration for prevention of macrovascular complications and deaths in obese cardiovascular high-risk patients with type 2 diabetes remains to be established and was therefore studied in this post hoc analysis of the Sibutramine Cardiovascular OUTcomes (SCOUT) trial, which enrolled
2012 Diabetologia Controlled trial quality: uncertain PubMed abstract
255. Effect of the G-protein β(3) subunit 825T allele on the change of body adiposity in obese female. (Abstract)
Effect of the G-protein β(3) subunit 825T allele on the change of body adiposity in obese female. No clinical studies on the lipolytic effect of guanine nucleotide-binding protein β3 subunit gene (GNB3) 825T polymorphism have been performed. This study was a subinvestigation of a 12-week randomized controlled trial (NCT01184560) for the additive effect of orlistat on sibutramine treatment. The analysis involved 101 obese females aged 18-49 years, genotyped at the GNB3 825 locus. To exclude any
2012 obesity & metabolism Controlled trial quality: uncertain
256. Intragastric balloon in association with lifestyle and/or pharmacotherapy in the long-term management of obesity. (Abstract)
in sequence as a maintenance strategy for weight loss.Fifty obese patients were recruited and randomly assigned to lifestyle modifications combined with either BIB for 6 months (n = 30) or sibutramine (pharmacotherapy group) for 1 year (n = 20). After BIB removal, patients were randomly assigned to either correct lifestyle (BIB/lifestyle) or lifestyle plus pharmacotherapy (BIB/pharmacotherapy).At 6 months, patients treated with BIB lost significantly (P < 0.05) more weight (percent of initial weight lost
2012 Obesity Surgery Controlled trial quality: uncertain
257. Prediction of weight loss and regain following dietary, lifestyle, and pharmacologic intervention. (Abstract)
Prediction of weight loss and regain following dietary, lifestyle, and pharmacologic intervention. To develop statistical models for predicting weight loss and regain, we analyzed the phenotypic responses in an outpatient study of 60 obese subjects randomized to one of three 12-week interventions, diet (-600 kcal) alone, diet with exercise, and diet with sibutramine. This was followed by 12 weeks of observation. The best of the "baseline covariates" models was one that incorporated intervention
2012 Clinical pharmacology and therapeutics Controlled trial quality: uncertain
258. Second-generation antipsychotic use in schizophrenia and associated weight gain: a critical review and meta-analysis of behavioral and pharmacologic treatments. (Abstract)
-induced weight gain in schizophrenia patients by searching PubMed and Google Scholar. A meta-analysis was performed to estimate and compare weight changes for various medications and behavioral interventions.Sample sizes generally were small. Clinical trials were 6 weeks to 1 year, and weight loss was modest with any treatment. Although several adjunctive pharmacologic treatments showed no weight loss, sibutramine, metformin, and topiramate showed some benefit. Amantadine and orlistat were somewhat
2012 Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists
259. A systematic review on use of Chinese medicine and acupuncture for treatment of obesity. (Abstract)
% CI: 1.37-2.46) and 2.14 (95% CI: 1.58-2.90) in favour of body weight reduction, with a mean difference in body weight reduction of 4.03 kg (95% CI: 2.22-5.85) and 2.76 kg (95% CI: 1.61-3.83) and a mean difference in BMI reduction of 1.32 kg m(-2) (95% CI: 0.78-1.85) and 2.02 kg m(-2) (95% CI: 0.94-3.10), respectively. Compared with the pharmacological treatments of sibutramine, fenfluramine or orlistat, CHM and acupuncture exhibited an RR of 1.11 (95% CI: 0.96-1.28) and 1.14 (95% CI: 1.03-1.25
2012 Obesity reviews : an official journal of the International Association for the Study of Obesity
260. Effect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials. (Full text)
) for LDL, a reduction of 0.12 mmol/L (95%CI: -0.20 to -0.04) for fasting glucose, 1.85 mmHg reduction (95%CI: -3.30 to -0.40) for SBP, and a reduction of 1.49 mmHg (95%CI: -2.39 to -0.58) for DBP. Sibutramine only showed effects on weight loss and triglycerides reduction with statistical significances. Rimonabant was associated with statistically significant effects on weight loss, SBP reduction and DBP reduction. No other significantly different effects were identified between anti-obesity therapy (...) and placebo.We identified that anti-obesity therapy was associated with a decrease of weight regardless of the type of the drug. Orlistat and rimonabant could lead to an improvement on cardiovascular risk factors. However, Sibutramine may have a direct effect on cardiovascular risk factors.
2012 PloS one PubMed abstract
To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>